Diode Laser Rhinitis Treatment Nerve Ablation

The patent replaces complex mechanical dissection and identification procedures with laser energy delivery. The laser fiber directly ablates the posterior nasal nerve through the middle turbinate without requiring mechanical dissection of the sphenopalatine artery or identification of the nerve, thus substituting a complex mechanical surgical system with a simpler energy-based system that achieves the same therapeutic effect.

The patent extracts and removes the posterior nasal nerve through laser ablation without requiring extraction or manipulation of surrounding complex structures like the sphenopalatine artery. By targeting only the nerve tissue through the middle turbinate, the procedure eliminates the need to handle complex vascular and neural structures, reducing surgical complexity while maintaining treatment effectiveness.

The patent applies local quality by delivering laser energy precisely to the posterior nasal nerve location without affecting surrounding structures. The laser fiber is positioned through the middle turbinate to target only the nerve tissue, creating localized ablation that spares the sphenopalatine artery (preventing bleeding) and the ophthalmic nerve (preventing eye dryness), thus achieving effective treatment while minimizing harmful side effects.

The patent converts the potential harm of laser energy into a beneficial selective ablation process. By controlling laser parameters and delivery location, the procedure uses thermal energy to precisely destroy only the posterior nasal nerve while the surrounding healthy tissues are protected, transforming what could be indiscriminate tissue damage into a selective therapeutic effect that eliminates the target nerve without causing complications.

The patent replaces the mechanical cryotherapy probe with a laser fiber delivery system. The laser fiber can be precisely positioned and oriented through the middle turbinate under endoscopic visualization, allowing accurate targeting of the posterior nasal nerve. This substitution enables better control over the treatment zone and improved precision compared to the bulkier cryotherapy device that relies on freezing diffusion.

The patent changes the physical parameter of the treatment modality from cryogenic temperatures to laser thermal energy. This parameter change allows for more precise control of the treatment zone, as laser energy can be delivered in a focused beam that can be precisely positioned and controlled in duration and intensity, whereas cryotherapy relies on thermal diffusion that is harder to confine to a precise target area.

The patent extracts the posterior nasal nerve treatment effect without requiring extraction or dissection of the sphenopalatine artery. By accessing the nerve through the middle turbinate and using laser ablation, the procedure eliminates the need to perform meticulous dissection of the SPA, thus achieving nerve targeting while removing the complex dissection step entirely.

The patent replaces the mechanical dissection process with laser energy delivery. Instead of using surgical instruments to dissect and identify the nerve through the sphenopalatine artery region, the laser fiber is positioned through the middle turbinate and directly ablates the nerve, substituting a complex mechanical identification and dissection system with a simpler energy-based ablation system.